[
    [
        {
            "time": "",
            "original_text": "【川财研究*医药生物】泰格医药（300347）：内生持续高增长，汇兑损益或缩窄——2018年半年度业绩预告点评",
            "features": {
                "keywords": [
                    "泰格医药",
                    "内生增长",
                    "汇兑损益",
                    "业绩预告",
                    "2018年半年度"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【川财研究*医药生物】泰格医药（300347）：内生持续高增长，汇兑损益或缩窄——2018年半年度业绩预告点评",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "[买入评级] 泰格医药(300347)：中报业绩超预期 推进方达医药香港上市",
            "features": {
                "keywords": [
                    "泰格医药",
                    "买入评级",
                    "中报业绩",
                    "超预期",
                    "方达医药",
                    "香港上市"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入评级] 泰格医药(300347)：中报业绩超预期 推进方达医药香港上市",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 4
            }
        }
    ]
]